In 2025, Bora Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 1,241.75a | 354.19a | 349.47a | |
Total Waste Recovered | 506.61a | 45.61a | N/A | |
Total Hazardous Waste Generated | 451.66a | 83.07a | 195.3a | |
Non-Hazardous Waste Disposed | 316.05a | 225.51a | 154.17a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Bora Pharmaceuticals generated a total of 1,242metric tonnes of waste.a
Of this amount, 40.8% of Bora Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 59.2% was disposed of through landfilling, incineration, or combustion.a
In 2025, Bora Pharmaceuticals reported a total waste generation of 1,242 metric tonnes, of which 40.8% was recovered through recycling, reuse, or composting.This moderate level of recovery indicates that Bora Pharmaceuticals is taking steps toward improving its waste diversion practices, though there is still room to enhance recycling and recovery efforts.a
Since 2023, Bora Pharmaceuticals's total waste generation increased by 255.32%, including a 250.59%increase in 2025, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.a
Over the same period, Bora Pharmaceuticals's waste recovery rate increased by 216.82%.a
In 2025, Bora Pharmaceuticals generated a total of 1,242 metric tonnes of waste.a
Of this amount, 36.37% of Bora Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.63.63% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, Bora Pharmaceuticals's total waste generation increased by 255.32%, including a 250.59% rise in 2025, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.a
Over the same period, the share of hazardous waste decreased by 34.91%, yet rose by 55.08% in 2025, potentially signaling operational variability, temporary setbacks, or less effective hazardous waste mitigation in the short term.a
Overall, Bora Pharmaceuticals's waste and hazardousness trends are mixed or inconclusive. A more detailed review of its materials, industry standards, and operational changes would help clarify the net environmental impact of its waste strategy.a
In 2025, Bora Pharmaceuticals reported that 452 metric tonnes of its total waste output were classified as hazardous. This represents 36.37% of its overall waste generation.a
The company treated this hazardous waste using a combination of methods.Only 7.21% of hazardous waste was recovered, meaning the vast majority was treated through disposal methods such as landfilling or incineration. This raises concerns about the environmental and health risks associated with Bora Pharmaceuticals’s current hazardous waste practices.a